支气管哮喘的药物治疗进展  

Progress of drug treatment of asthma

作　　者：梅周芳[1] 吴宜[1] MEI Zhou-fang WU Yi(The Fifth People＇s Hospital of Shanghai, Fudan University, Shanghai 200240, Chin)

机构地区：[1]复旦大学附属上海市第五人民医院,上海200240

出　　处：《中国医学创新》2017年第8期145-148,共4页Medical Innovation of China

摘　　要：支气管哮喘是多种炎症细胞如肥大细胞和嗜酸性粒细胞等,以及免疫细胞如T淋巴细胞等共同参与的一种以气道慢性炎症为主要特征的呼吸系统疾病。近年来对支气管哮喘的病因、发病机制和治疗机理的深入研究,尤其是与治疗相关的临床随机对照试验结果的发表,为支气管哮喘的药物治疗提供了新的指导方向。虽然支气管哮喘尚不能根治,但通过合理的药物选择和治疗能使哮喘症状在短时间内得到很好的控制,减轻患者的痛苦。本文就目前支气管哮喘治疗中常见药物种类、机制、在治疗中的地位以及新型哮喘治疗药物进行综述,以利于支气管哮喘的合理规范化治疗。Bronchial asthma is a type of chronic inflammatory airway disease, which involves eosinophils, mast ceils and T lymphocytes.In recent years, more progress are made in its etiology, pathogenesis, and mechanism of drug action, especially some randomized, controlled clinical studies have been published, drug treatment for asthma also have a guidance.Although asthma can＇t be cured, but rational drug selection can make the disease under control in shortest time, reducing the suffering.under current treatment of bronchial asthma, this paper reviewed common types of drugs, mechanism, status in the treatment of asthma and new treatments, in order to facilitate a reasonable standard treatment of bronchial asthma.

关 键 词：哮喘 药物治疗 进展 

分 类 号：R562.25[医药卫生—呼吸系统]